DHEA

Mechanism of Action

The evidence provided contains limited information about DHEA's specific mechanism of action at the molecular and physiological level. Based on the available clinical trial data, DHEA appears to function primarily as a steroid hormone precursor, but detailed mechanistic pathways are not well-documented in these studies.

The clinical trials suggest DHEA works through conversion to active hormones:

Hormonal Conversion Pathway

• Prasterone (synthetic DHEA) is investigated in postmenopausal women for vulvovaginal atrophy treatment (NCT04982692, NCT06611514), suggesting it acts by converting to estrogens and androgens locally in target tissues
• Studies examining DHEA's effects on ovarian reserve markers (NCT01129830, NCT02150330) indicate it may influence reproductive hormone pathways, though specific mechanisms are not detailed

Potential Cellular Effects

• One completed study investigated DHEA's effects on cumulus cell gene expression during ovarian stimulation (NCT02150330), suggesting it may modulate cellular function at the gene expression level
• The epidemiological study linking DHEA sulfate to coronary heart disease mortality (NCT00005246) implies cardiovascular effects, though mechanisms are not specified

Evidence Limitations
The provided evidence lacks detailed molecular mechanistic studies. The PubMed findings focus on other compounds and pathways (STEAP4, mesenchymal stem cells, GATA1) rather than DHEA's specific mechanism of action. Most clinical trials are observational or focus on clinical outcomes rather than mechanistic pathways.

Disclaimer: This information is for educational purposes only and should not replace professional medical advice. Consult healthcare providers for personalized treatment decisions.

More comprehensive mechanistic research would be needed to fully understand DHEA's molecular pathways and physiological effects.

DHEA (dehydroepiandrosterone) is primarily investigated for reproductive and hormonal conditions, with most clinical research focusing on specific populations and indications.

Reproductive Health Applications

Diminished Ovarian Reserve
Clinical trials have examined DHEA supplementation in women with diminished ovarian reserve, a condition affecting fertility. One Phase 3 study investigated how DHEA affects gene expression in cumulus cells during controlled ovarian hyperstimulation in this patient population, though detailed results are not provided in the available evidence. Another early-phase trial examining DHEA's effects on ovarian reserve markers was terminated, limiting conclusions about efficacy in this indication.

Postmenopausal Conditions
DHEA in the form of prasterone (intravaginal DHEA) has been studied for postmenopausal vulvovaginal atrophy and genitourinary syndrome of menopause (GSM). A completed Phase 3 trial evaluated intravaginal prasterone for vulvovaginal atrophy, and another Phase 3 study is planned to examine its effects on GSM symptoms specifically in postmenopausal women with a history of breast cancer. These applications focus on local hormonal effects rather than systemic supplementation.

Cardiovascular Research

Limited evidence exists for DHEA's role in cardiovascular health. One epidemiological study examined the relationship between DHEA sulfate levels and coronary heart disease mortality, though this was observational rather than interventional research.

Evidence Limitations

The available clinical trial evidence for DHEA is limited, with several studies either terminated or lacking detailed outcome data. While the compound has been investigated across reproductive health applications, the evidence base appears incomplete for drawing definitive conclusions about clinical efficacy in most indications.

This information is for educational purposes only and should not replace professional medical advice. Consult with a healthcare provider before considering DHEA supplementation.

Safety Profile of DHEA

Important Note: The evidence provided for DHEA safety is extremely limited. The available studies focus primarily on hormonal research and reproductive health conditions rather than comprehensive safety data for DHEA supplementation.

Known Side Effects

Evidence is very thin regarding specific side effects of DHEA supplementation. The provided research does not include comprehensive safety studies or adverse event reporting from DHEA trials. Most available clinical trials listed show completed or ongoing studies but lack detailed safety outcome data in the evidence provided.

Contraindications

Based on the limited evidence available, specific contraindications cannot be definitively established from these sources. However, given DHEA's role as a hormone precursor that can convert to both androgens and estrogens, caution would be warranted in hormone-sensitive conditions.

Drug Interactions

No drug interaction data is available in the provided evidence. This represents a significant knowledge gap that requires consultation with healthcare providers before combining DHEA with other medications.

Populations That Should Exercise Caution

The evidence suggests particular considerations for:

• Women with hormone-sensitive breast cancer: One ongoing Phase 3 trial (NCT06611514) is specifically studying intravaginal prasterone (a DHEA derivative) in women with previous breast cancer, indicating this population requires careful evaluation
• Reproductive-age women: Several studies focus on DHEA's effects on reproductive hormones and ovarian function, suggesting potential impacts on fertility and menstrual cycles
• Postmenopausal women: Clinical trials indicate use in this population, but comprehensive safety data is not provided in the available evidence

Evidence Limitations

The safety profile presented here is severely limited by the scope of available evidence. The provided studies primarily focus on:

• Reproductive hormone research
• Specific conditions like polycystic ovary syndrome
• Limited clinical trial listings without detailed safety outcomes

Critical gaps include:

• Long-term safety data
• Comprehensive adverse event profiles
• Drug interaction studies
• Safety in special populations (pregnancy, pediatric, hepatic/renal impairment)

Medical Disclaimer: This information is for educational purposes only and should not replace professional medical advice. Anyone considering DHEA supplementation should consult with a qualified healthcare provider who can assess individual risk factors and potential interactions with existing medications or conditions.

Research Papers and Clinical Trials

Recent research on DHEA (dehydroepiandrosterone) spans several reproductive health conditions, though the evidence base remains limited with mixed findings.

Clinical Trial Evidence

The most robust clinical evidence comes from completed Phase 3 trials examining prasterone (a synthetic form of DHEA) as vaginal inserts for postmenopausal women. One completed study (NCT04982692) investigated INTRAROSA® vaginal inserts for vulvovaginal atrophy, while another Phase 3 trial is planned for women with breast cancer history experiencing genitourinary syndrome of menopause (NCT06611514).

For fertility applications, a completed Phase 3 trial (NCT02150330) examined DHEA supplementation effects on gene expression in cumulus cells during controlled ovarian hyperstimulation in women with diminished ovarian reserve. However, another early-phase study (NCT01129830) investigating DHEA's effects on ovarian reserve markers was terminated, indicating potential challenges in this research area.

Observational Research

An epidemiological study (NCT00005246) examined the relationship between DHEA sulfate levels and coronary heart disease mortality, highlighting DHEA's broader health implications beyond reproductive function.

Related Research Context

While not directly testing DHEA, recent 2026 publications provide relevant context for conditions where DHEA supplementation is sometimes considered. Studies have examined cellular mechanisms in polycystic ovary syndrome (PCOS), including granulosa cell dysfunction and autophagy pathways. Additional research has investigated how caloric restriction and time-restricted eating affect reproductive hormones in women.

Evidence Limitations

The clinical trial evidence for DHEA is notably sparse, with one fertility-related study terminated and limited completed trials focusing primarily on topical vaginal applications rather than systemic supplementation. Most recent research papers address related reproductive conditions but do not directly evaluate DHEA interventions.

Disclaimer: This information is for educational purposes only and should not replace consultation with healthcare providers for individual medical decisions.

DHEA Dosing and Administration Protocols

Based on the available clinical trial evidence, DHEA (dehydroepiandrosterone) protocols vary significantly depending on the indication and formulation used.

Vaginal Prasterone (DHEA) for Postmenopausal Conditions

For vulvovaginal atrophy and genitourinary syndrome of menopause, intravaginal prasterone (a form of DHEA) has been studied in Phase 3 clinical trials. The commercial formulation INTRAROSA® consists of vaginal inserts, though specific dosing details are not provided in the available evidence.

DHEA for Diminished Ovarian Reserve

Limited evidence exists for DHEA supplementation in women with diminished ovarian reserve. One Phase 3 study examined DHEA effects on cumulus cell gene expression during controlled ovarian hyperstimulation, while an early-phase study investigating DHEA's effects on ovarian reserve markers was terminated. Specific dosing protocols for this indication are not detailed in the available evidence.

Evidence Limitations

The current evidence base provides minimal information about specific DHEA dosing regimens, administration frequencies, or treatment durations. Most studies focus on outcomes rather than detailed protocol specifications. Additionally, one study investigating ovarian reserve effects was terminated, limiting available data for this indication.

Disclaimer: This information is for educational purposes only and does not constitute personalized medical advice. DHEA supplementation should only be undertaken under the supervision of a qualified healthcare provider who can determine appropriate dosing based on individual medical history, current health status, and treatment goals. Healthcare providers should consult current prescribing information and clinical guidelines when considering DHEA therapy.

Outcomes

The available evidence on DHEA outcomes is limited and primarily focused on specific reproductive health applications. Based on the clinical trials data, the following measurable results have been reported:

Reproductive Health Outcomes

Diminished Ovarian Reserve: One completed Phase 3 trial (NCT02150330) examined DHEA supplementation effects on cumulus cell gene expression in women with diminished ovarian reserve undergoing controlled ovarian hyperstimulation. However, specific outcome measures and results are not detailed in the available trial registry information.

A separate early-phase trial (NCT01129830) investigating DHEA's effect on ovarian reserve markers in women with diminished ovarian reserve was terminated, limiting available outcome data from this study.

Postmenopausal Vulvovaginal Atrophy: A completed Phase 3 trial (NCT04982692) evaluated intravaginal prasterone (DHEA) for postmenopausal vulvovaginal atrophy, though specific outcome measurements are not provided in the registry data.

Cardiovascular Outcomes

One epidemiological study (NCT00005246) examined the relationship between DHEA sulfate levels and coronary heart disease mortality, but measurable outcomes from this observational research are not detailed in the available information.

Evidence Limitations

The strength of evidence for DHEA outcomes is notably weak based on the available data. While several clinical trials have been completed, the specific measurable results—such as biomarker changes, symptom improvement scores, or clinical endpoints—are not reported in the trial registry information provided. Additionally, one relevant trial was terminated, further limiting the evidence base.

The PubMed literature provided does not contain studies directly evaluating DHEA outcomes, instead focusing on related hormonal and reproductive mechanisms that may be tangentially relevant but do not provide direct evidence of DHEA therapeutic effects.

Note: This summary is based on limited clinical trial registry information. Consult healthcare providers for personalized medical advice regarding DHEA supplementation.